Core Insights - Sernova Biotherapeutics has appointed Dr. Pericles Calias as Chief Development Officer and Head of R&D, enhancing its operational depth and expertise in cell therapy [1][2] Company Overview - Sernova Biotherapeutics is a clinical-stage company focused on developing regenerative medicine therapeutics, specifically its Cell Pouch Bio-hybrid Organ aimed at providing a functional cure for type 1 diabetes (T1D) [4] - The company collaborates with Evotec to create bio-hybrid organs that integrate human donor cells or stem-cell derived islet-like clusters with the Cell Pouch [4] Leadership and Expertise - Dr. Calias brings over 20 years of global operational experience in drug product development, having held leadership roles at various life sciences companies [2] - His background includes securing regulatory approvals and leading R&D efforts in areas such as rare diseases and autoimmune disorders [2][3] - Dr. Calias holds a Ph.D. in Bio-Organic Chemistry and is an inventor on over 40 patents, contributing significantly to regulatory filings [3]
Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D